SCHEMBL3013116

SCHEMBL3013116

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
USP2 O75604 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
RAB9A P51151 1/20 0.37
POLB P06746 3/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
MAPK1 P28482 2/20 0.37
SCN1A P35498 1/20 0.36
SCN8A Q9UQD0 1/20 0.36
OXTR P30559 4/20 0.36
AVPR1A P37288 4/20 0.36
AVPR1B P47901 4/20 0.36
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016085 0.93 MAPT (0.39) MAPTHCRTR1HCRTR2USP2RECQL
SCHEMBL2997801 0.92 SMN1; SMN2 (0.39) MAPTHCRTR1HCRTR2USP2RECQL
SCHEMBL3013069 0.92 TP53 (0.40) MAPTTP53SMN1; SMN2RAB9ALMNA
SCHEMBL3018344 0.91 HTR2A (0.41) MAPTSMN1; SMN2RAB9AALDH1A1LMNA
SCHEMBL3013270 0.91 MAPT (0.44) MAPTUSP2RECQLHSD17B10TP53
SCHEMBL3020208 0.91 DRD2 (0.35) MAPTTP53SMN1; SMN2RAB9AALDH1A1
SCHEMBL3002470 0.91 TP53 (0.38) MAPTTP53SMN1; SMN2RAB9APOLB
SCHEMBL3009255 0.90 HTR2A (0.37) MAPTSMN1; SMN2RAB9AALDH1A1SCN1A
SCHEMBL3014002 0.90 ALDH1A1 (0.38) MAPTUSP2RECQLHSD17B10TP53
SCHEMBL3013134 0.89 RAB9A (0.41) MAPTHCRTR1HCRTR2HSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HCRTR1 2170/4885HCRTR2 1972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.